BMO Capital lowered its price target on aTyr Pharma (NASDAQ: LIFE) to $2.00 (from $4.00) while maintaining a Market Perform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

aTyr Pharma (LIFE) PT Lowered to $3 at Piper JaffrayMay 15, 2018 1:34 AM UPDATE: Citi Downgrades aTyr Pharma (LIFE) to SellMay 14, 2018 4:18 PM aTyr Pharma (LIFE) Reports In-Line Q1 EPSMay 14, 2018 6:47 AM Form 8-K aTYR PHARMA INC For: May 10May 14, 2018 6:45 AM aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate RestructuringMay 14, 2018 6:45 AM